Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción
ilustraciones a blanco y negro, diagramas
- Autores:
-
Arbeláez Ariza, Carlos Emilio
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad Nacional de Colombia
- Repositorio:
- Universidad Nacional de Colombia
- Idioma:
- spa
- OAI Identifier:
- oai:repositorio.unal.edu.co:unal/85485
- Palabra clave:
- 610 - Medicina y salud::615 - Farmacología y terapéutica
Unidades de cuidados intensivos
Negativa del paciente al tratamiento
Cumplimiento de la medicación
Errores de medicación
Intensive care units
Treatment refusal
Medication adherence
Medication errors
Unidad de cuidados intensivos
Eventos adversos
Prevención
Errores de medicación
Intensive care unit
Adverse events
Prevention
Medication errors
- Rights
- openAccess
- License
- Atribución-NoComercial 4.0 Internacional
| id |
UNACIONAL2_5b27683440f6e8b7dfec5a8bdc37ae57 |
|---|---|
| oai_identifier_str |
oai:repositorio.unal.edu.co:unal/85485 |
| network_acronym_str |
UNACIONAL2 |
| network_name_str |
Universidad Nacional de Colombia |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| dc.title.translated.eng.fl_str_mv |
Pharmacological Counseling to Prevent Adverse Events in an Intensive Care Unit at a University Hospital in Bogotá PHASE 1: Frequency of Adverse Events and Prescription Errors |
| title |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| spellingShingle |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción 610 - Medicina y salud::615 - Farmacología y terapéutica Unidades de cuidados intensivos Negativa del paciente al tratamiento Cumplimiento de la medicación Errores de medicación Intensive care units Treatment refusal Medication adherence Medication errors Unidad de cuidados intensivos Eventos adversos Prevención Errores de medicación Intensive care unit Adverse events Prevention Medication errors |
| title_short |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| title_full |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| title_fullStr |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| title_full_unstemmed |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| title_sort |
Asesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción |
| dc.creator.fl_str_mv |
Arbeláez Ariza, Carlos Emilio |
| dc.contributor.advisor.spa.fl_str_mv |
Maldonado, Carlos Orozco, José Londoño, Darío |
| dc.contributor.author.spa.fl_str_mv |
Arbeláez Ariza, Carlos Emilio |
| dc.contributor.orcid.spa.fl_str_mv |
Arbeláez Ariza, Carlos Emilio |
| dc.subject.ddc.spa.fl_str_mv |
610 - Medicina y salud::615 - Farmacología y terapéutica |
| topic |
610 - Medicina y salud::615 - Farmacología y terapéutica Unidades de cuidados intensivos Negativa del paciente al tratamiento Cumplimiento de la medicación Errores de medicación Intensive care units Treatment refusal Medication adherence Medication errors Unidad de cuidados intensivos Eventos adversos Prevención Errores de medicación Intensive care unit Adverse events Prevention Medication errors |
| dc.subject.decs.spa.fl_str_mv |
Unidades de cuidados intensivos Negativa del paciente al tratamiento Cumplimiento de la medicación Errores de medicación |
| dc.subject.decs.eng.fl_str_mv |
Intensive care units Treatment refusal Medication adherence Medication errors |
| dc.subject.proposal.spa.fl_str_mv |
Unidad de cuidados intensivos Eventos adversos Prevención Errores de medicación |
| dc.subject.proposal.eng.fl_str_mv |
Intensive care unit Adverse events Prevention Medication errors |
| description |
ilustraciones a blanco y negro, diagramas |
| publishDate |
2024 |
| dc.date.accessioned.none.fl_str_mv |
2024-01-29T18:24:52Z |
| dc.date.available.none.fl_str_mv |
2024-01-29T18:24:52Z |
| dc.date.issued.none.fl_str_mv |
2024-01 |
| dc.type.spa.fl_str_mv |
Trabajo de grado - Maestría |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/masterThesis |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TM |
| status_str |
acceptedVersion |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.unal.edu.co/handle/unal/85485 |
| dc.identifier.instname.spa.fl_str_mv |
Universidad Nacional de Colombia |
| dc.identifier.reponame.spa.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
| dc.identifier.repourl.spa.fl_str_mv |
https://repositorio.unal.edu.co/ |
| url |
https://repositorio.unal.edu.co/handle/unal/85485 https://repositorio.unal.edu.co/ |
| identifier_str_mv |
Universidad Nacional de Colombia Repositorio Institucional Universidad Nacional de Colombia |
| dc.language.iso.spa.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.spa.fl_str_mv |
Heard GC, Sanderson PM, Thomas RD. Barriers to adverse event and error reporting in anesthesia. Anesth Analg. 2012;114(3):604-614. Baillie M. An Account of a Particular Change of Structure in the Human Ovarium. L Med J. 1789;10:322-332 Wiedemann HR. [Indication of a current association of hypoplastic and aplastic limb malformations.]. Medizinische Welt. 1961;37:1863-1866. Auzépy P, Durocher A, Gay R, et al. [Severe drug complications: current prevalence amongst patients admitted to adult intensive care units (author’s transl)]. Nouv Press Med. 1979;8(16):1315-1318. Farina ML. Epidemiology of adverse drug reactions in intensive care units. A multicentre prospective survey. Italian Group on Intensive Care Evaluation (IGICE). Eur J Clin Pharmacol. 1987;31(5):507-512 Michel P, Quenon JL, De Sarasqueta AM, Scemama O. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ. 2004;328(7433):199-202 Laher AE, Enyuma CO, Gerber L, Buchanan S, Adam A, Richards GA. Medication Errors at a Tertiary Hospital Intensive Care Unit. Cureus. 2021;13(12): e20374 Albayrak A, Başgut B, Bıkmaz GA, Karahalil B. Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Serv Res. 2022;22(1): 79 Sendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA. Clinical and economic impact of adverse drug reactions in hospitalised patients: prospective matched nested case-control study in Ethiopia. BMJ Open. 2023;13(6): e073777 da Costa TX, de Almeida Pimenta Cunha MD, do Vale Bezerra PK, Azeredo FJ, Martins RR, Oliveira AG. Incidence of Adverse Drug Reactions in High-Risk Pregnancy: A Prospective Cohort Study in Obstetric Intensive Care. Eur J Clin Pharmacol. 2020;76(2):291-298. Nazer LH, Hawari F, Al-Najjar T. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes. J Pharm Pract. 2014;27(2):208-213. Benkirane RR, R-Abouqal R, Haimeur CC, et al. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf. 2009;5(1):16-22. Kosenow W, Pfeiffer RA. Micromelia, Haemangioma und Duodenal Stenosis Exhibit, German Pediatric Society, Kassel, 1960. Monatsschr Kinderheilkd. 1961;109:227. UMC. About the WHO Programme for International Drug Monitoring. Accessed December 27, 2023. https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/ UMC. The beginner’s guide to pharmacovigilance. Published 2023. Accessed December 27, 2023. https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/the-beginner-s-guide-to-pharmacovigilance/ Brown S, Black K, Mrochek S, et al. RADARx: Recognizing, Assessing, and Documenting Adverse Rx events. Proc AMIA Symp. Published online 2000:101-105. Bates DW, Cullen DJ, Laird N, et al. Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. JAMA. 1995;274(1):29-34. Leape LL, Bates DW, Cullen DJ, et al. Systems Analysis of Adverse Drug Events. JAMA. 1995;274(1):35-43. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87-94. Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120. Fortescue EB, Kaushal R, Landrigan CP, et al. Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. Pediatrics. 2003;111(4 Pt 1):722-729. Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am J Health Syst Pharm. 1998;55(2):165-166 SERVICES DOHAH. Guideline for Postmarketing Reporting of Adverse Drug Experiences.; 1992. https://www.fda.gov/media/83280/download Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet (London, England). 2000;356(9237):1255-1259 Cobert B, Biron P. Pharmacovigilance from a to Z : Adverse Drug Event Surveillance. Blackwell Science; 2002 Harmonisation International Conference on. E 2 D: Postapproval Safety Data Management.; 2003. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-d-postapproval-safety-data-management-step-5_en.pdf Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized Surveillance of Adverse Drug Events in Hospital Patients. JAMA. 1991;266(20):2847-2851 Schlienger RG, Lüscher TF, Schoenenberger RA, Haefeli WE. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci. 1999;21(3):110-115. Andrews LB, Stocking C, Krizek T, et al. An alternative strategy for studying adverse events in medical care. Lancet (London, England). 1997;349(9048):309-313 Institute of Medicine (US) Committee on Quality of Health Care in America. To Err Is Human: Building a Safer Health System. (Kohn LT, Corrigan JM, Molla S. D, eds.). National Academy of Sciences; 2000 World Health Organization. The Importance of Pharmacovigilance: An Essential Tool. World Health Organization; 2002. UMC. Glossary of Pharmacovigilance Terms.; 2022. https://learning.who-umc.org/files/114398/SCORM_867007413/scormdriver/indexAPI.html Bates DW, Boyle DL, Vliet MBV, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10(4):199-205. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001;161(19):2317-2323. Hutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HHP. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39(7):533-542. doi:10.1016/0021-9681(86)90198-0 Putriana NA, Rusdiana T, Rostinawati T, Akbar MR, Destiani DP. Evaluation of adverse drug reaction in patients warfarin therapy. J Adv Pharm Technol Res. 2022;13(4):291-295. Martys CR. Adverse reactions to drugs in general practice. Br Med J. 1979;2(6199):1194-1197 Ejeta F, Aferu T, Feyisa D, et al. Adverse Drug Reaction and Its Predictors Among Psychiatric Patients Taking Psychotropic Medications at the Mizan-Tepi University Teaching Hospital. Neuropsychiatr Dis Treat. 2021;17:3827-3835 Abah IO, Dayom WD, Dangiwa DA, et al. Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected Cohort. Afr Health Sci. 2021;21(3):1027-1039 Sankhi S, Marasine NR, Sankhi S, Lamichhane R. Adverse Drug Reaction due to Antidepressants among Patients with Depression in a Private Psychiatric Hospital of Nepal. Biomed Res Int. 2020; 16:2020:6682928 Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. JAMA. 1997;277(4):301-306. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies. JAMA. 1998;279(15):1200-1205. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2): e4439 Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Heal care J Int Soc Qual Heal Care. 2003;15 Suppl 1(SUPPL. 1): i49-59. Seddon ME, Jackson A, Cameron C, et al. The Adverse Drug Event Collaborative: a joint venture to measure medication-related patient harm. N Z Med J. 2012;126(1368):9-20 Vargas E, Terleira A, Hernando F, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31(3):694-698. Hallas J, Gram L, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol. 1992;33(1):61-68 Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12(4):280-285 Cooke DI, van der Merwe W, Pudifin DJ. Hospital admissions for adverse reactions to drugs and deliberate self-poisoning. S Afr Med J. 1985;67(19):770-772 Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA. 1974;228(6):713-717 Rostin M, Pascaud A, Lauque D, Sorbette F, Carles P, Montastruc JL. [An intensive survey of drug surveillance in a medical admissions department]. La Rev Med interne. 1987;8(2):173-179 Hallas J, Haghfelt T, Gram LF, Grodum E, Damsbo N. Drug related admissions to a cardiology department; frequency and avoidability. J Intern Med. 1990;228(4):379-384 Lakshmanan MC, Hershey CO, Breslau D. Hospital admissions caused by iatrogenic disease. Arch Intern Med. 1986;146(10):1931-1934 Einarson TR, Gutierrez LM, Rudis M. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7-8):832-840 Karande S, Gogtay NJ, Kshirsagar NA. Improving drug safety monitoring. Indian Pediatr. 2003;40(12):1167-1175. Winterstein AG, Sauer BC, Hepler CD, Poole C, Suárez EC, Kaiser JM. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-1248. McDonnell PJ, Jacobs MR, Monsanto HA, Kaiser JM. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331-1336 Schneider PJ, Gift MG, Lee YP, Rothermich EA, Sill BE. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm. 1995;52(21):2415-2418. Bates DW, Spell N, Cullen DJ, et al. The Costs of Adverse Drug Events in Hospitalized Patients. JAMA. 1997;277(4):307-311 White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445-458. Potts AL, Barr FE, Gregory DF, Wright L, Patel NR. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics. 2004;113(1 Pt 1):59-63 Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120 Burnum JF. Letter: Preventability of adverse drug reactions. Ann Intern Med. 1976;85(1):80-81 Porter J, Jick H. Drug-related deaths among medical inpatients. JAMA. 1977;237(9):879-881 Melmon KL. Preventable drug reactions--causes and cures. N Engl J Med. 1971;284(24):1361-1368 Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8(6):289-294 Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116 Field TS, Gurwitz JH, Harrold LR, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc. 2004;11(6):492-498 Silva CMD da, Besen BAMP, Nassar AP. Characteristics of critically ill patients with cancer associated with intensivist’s perception of inappropriateness of ICU admission: A retrospective cohort study. J Crit Care. 2024;79:154468 Sánchez-Sánchez MM, Campos-Asensio C, Arias-Rivera S. Workloads of intensive care nurses. Validity of their estimation using mobile applications and comparison with Nursing Activities Score. Systematised review of the literature. Enferm intensiva. Published online December 12, 2023 Leviatan I, Oberman B, Zimlichman E, Stein GY. Associations of physicians’ prescribing experience, work hours, and workload with prescription errors. J Am Med Inform Assoc. 2021;28(6):1074-1080. Oliveira AC de, Garcia PC, Nogueira L de S. Nursing workload and occurrence of adverse events in intensive care: a systematic review. Rev Esc Enferm USP. 2016;50(4):683-694. Dagdelen MS, Gulen D, Ceylan I, Girgin NK. Evaluation of potential drug-drug interactions in intensive care unit. Eur Rev Med Pharmacol Sci. 2021;25(18):5801-5806 Arab A, Sheikh-Germchi Z, Habibzadeh S, Sadeghiye-Ahari S, Mostafalou S. Frequency, Predictors, and Outcomes of the Potential Drug-Drug Interactions in the ICUs of Teaching Hospitals in Ardabil, Northwest of Iran During 2019-2020. Hosp Pharm. 2023;58(5):484-490 Klopotowska JE, Leopold JH, Bakker T, et al. Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A multicentre retrospective observational study. Br J Clin Pharmacol. 2024;90(1):164-175 Cantor N, Durr KM, McNeill K, et al. Increased Mortality and Costs Associated with Adverse Events in Intensive Care Unit Patients. J Intensive Care Med. 2022;37(8):1075-1081 Houso A, Hamdan M, Falana H. Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2022;30(12):1718-1724 Alghamdi AA, Keers RN, Sutherland A, Ashcroft DM. Prevalence and Nature of Medication Errors and Preventable Adverse Drug Events in Paediatric and Neonatal Intensive Care Settings: A Systematic Review. Drug Saf. 2019;42(12):1423-1436 Resnik DB, Stewart CN. Misconduct versus honest error and scientific disagreement. Account Res. 2012;19(1):56-63 Liker JK. The Toyota Way: 14 Management Principles from the World’s Greatest Manufacturer. 2 ED. McGraw-Hill; 2021. Jeremy LE, Soong JL, Lie SA. A cost avoidance study of critical care pharmacists’ interventions in a tertiary institution in Singapore. Am J Health Syst Pharm. 2023;80(5):267-283 Althomali A, Altowairqi A, Alghamdi A, et al. Impact of Clinical Pharmacist Intervention on Clinical Outcomes in the Critical Care Unit, Taif City, Saudi Arabia: A Retrospective Study. Pharm (Basel, Switzerland). 2022;10(5):108 Muñoz-Pichuante D, Villa-Zapata L. Benefit of Incorporating Clinical Pharmacists in an Adult Intensive Care Unit: A Cost-saving Study. J Clin Pharm Ther. 2020;45(5):1127-1133 Leache L, Aquerreta I, Aldaz A, Monedero P, Idoate A, Ortega A. Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients. Res Social Adm Pharm. 2020;16(9):1285-1289 |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.license.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional |
| dc.rights.uri.spa.fl_str_mv |
http://creativecommons.org/licenses/by-nc/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Atribución-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
xiv, 84 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.coverage.city.none.fl_str_mv |
Bogotá |
| dc.publisher.spa.fl_str_mv |
Universidad Nacional de Colombia |
| dc.publisher.program.spa.fl_str_mv |
Bogotá - Ciencias - Maestría en Ciencias - Farmacología |
| dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
| dc.publisher.place.spa.fl_str_mv |
Bogotá, Colombia |
| dc.publisher.branch.spa.fl_str_mv |
Universidad Nacional de Colombia - Sede Bogotá |
| institution |
Universidad Nacional de Colombia |
| bitstream.url.fl_str_mv |
https://repositorio.unal.edu.co/bitstream/unal/85485/1/license.txt https://repositorio.unal.edu.co/bitstream/unal/85485/2/79952694.2007.pdf https://repositorio.unal.edu.co/bitstream/unal/85485/3/79952694.2007.pdf.jpg |
| bitstream.checksum.fl_str_mv |
eb34b1cf90b7e1103fc9dfd26be24b4a 57aa22fed62f65faad7f720636e99eb1 7c153bd48a516976016a00b09eec12e6 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Universidad Nacional de Colombia |
| repository.mail.fl_str_mv |
repositorio_nal@unal.edu.co |
| _version_ |
1814089807845916672 |
| spelling |
Atribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Maldonado, Carlos98ce854c964d2bf68b51136d70ec7cd7Orozco, Joséc21268e50aabe5f6be3c87763d499e24Londoño, Darío25a78da9498a2a413f14b2bd9d38006cArbeláez Ariza, Carlos Emilio07cefd00130b49838d9a0c6e1dda06fdArbeláez Ariza, Carlos Emilio2024-01-29T18:24:52Z2024-01-29T18:24:52Z2024-01https://repositorio.unal.edu.co/handle/unal/85485Universidad Nacional de ColombiaRepositorio Institucional Universidad Nacional de Colombiahttps://repositorio.unal.edu.co/ilustraciones a blanco y negro, diagramasAsesoría Farmacológica Para Prevenir Eventos Adversos En Una Unidad De Cuidados Intensivos En Un Hospital Universitario En Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripción Se llevó a cabo un estudio observacional de cohorte en la Unidad de Cuidados Intensivos (UCI) del Hospital Universitario de San Ignacio entre julio y agosto de 2005, que incluyó 63 pacientes y registró 2209 órdenes médicas en 250 días-paciente de seguimiento. Se encontró que 54.9% de las órdenes iniciales y 32.3% de las órdenes de seguimiento presentaban errores de prescripción, siendo más comunes la administración de medicamentos contraindicados, interacciones de alto riesgo y el uso fuera de indicaciones aprobadas. Se encontró que las órdenes con estos errores tenían una frecuencia de efectos adversos del 32.9%, mientras que las órdenes sin errores mostraban un 22.9%. Estos datos sugieren que aproximadamente el 30.4% de los efectos adversos podrían haberse evitado mediante una intervención que identificara y previniera estos errores de prescripción. Además, se identificó que de los 110 medicamentos empleados en la UCI, diez causaron el 50% de los efectos adversos y veinticinco medicamentos el 80%. Se propone la intervención de un farmacólogo en la UCI para analizar las prescripciones, detener el uso de medicamentos contraindicados, prevenir interacciones de alto riesgo y corregir el uso fuera de indicaciones aprobadas. Esta intervención también incluiría la identificación temprana de errores de prescripción y eventos adversos, el apoyo en su manejo y el diseño de herramientas educativas continuas para mejorar los hábitos de prescripción médica y, por ende, la efectividad del tratamiento farmacológico en la UCI. (Texto tomado de la fuente)Pharmacological Counseling to Prevent Adverse Events in an Intensive Care Unit at a University Hospital in Bogotá PHASE 1: Frequency of Adverse Events and Prescription Errors An observational cohort study was conducted in the Intensive Care Unit (ICU) of San Ignacio University Hospital during July and August 2005. The study included 63 patients and recorded 2209 medical orders during 250 patient-days of follow-up. The findings revealed that 54.9% of the initial orders and 32.3% of the follow-up orders presented prescription errors, with the most common being administration of contraindicated medications, high-risk interactions, and off-label use. Orders with these errors showed an adverse effects frequency of 32.9%, while error-free orders displayed 22.9%. These results suggest that approximately 30.4% of adverse effects could have been prevented through intervention identifying and preventing these prescription errors. Furthermore, it was identified that ten medications caused 50% of the adverse effects, and twenty-five medications accounted for 80%, highlighting the importance of prioritizing these drugs in risk mitigation strategies. Consequently, the intervention of a pharmacologist in the ICU is proposed to analyze prescriptions, halt the use of contraindicated medications, prevent high-risk interactions, and correct off-label use. This intervention would also involve early identification of prescription errors and adverse events, support in their management, and the design of continuous educational tools to enhance medical prescription habits and thereby improve the effectiveness of pharmacological treatment in the ICU.MaestríaMagíster en Ciencias - FarmacologíaEl Hospital Universitario de San Ignacio ha implementado el sistema SAHI® de Historia Clínica Digital, permitiendo la consulta en tiempo real de la información de pacientes desde terminales internas. El estudio realizado es retrospectivo, basado en datos recopilados en tiempo real, sin contacto adicional con pacientes o personal médico. La vinculación de pacientes se realiza a través del sistema SAHI®, facilitando la búsqueda y seguimiento manual de pacientes hospitalizados, con datos registrados diariamente. La información se recopila en formularios y se transfiere manualmente a una base de datos en Excel, que luego se exporta a Minitab para el análisis. En cuanto a las definiciones de caso, se determina que un paciente experimenta un efecto adverso si presenta síntomas o variaciones negativas en pruebas diagnósticas después de la administración de un medicamento, sin explicación lógica relacionada con la patología del paciente. Los errores de prescripción se definen como desviaciones del uso racional del medicamento e incluyen indicación sin justificación, administración en contraindicación, errores posológicos y contraindicaciones que se asocian con toxicidad. La evaluación se realiza utilizando registros sanitarios, bases de datos como Micromedex®, y búsquedas bibliográficas. En términos de análisis estadístico, se emplea una fórmula de proporciones para determinar el tamaño muestral, ya que no se contaba con información previa sobre tasas de errores de medicación o frecuencia de efectos adversos. Las variables del paciente y las órdenes médicas se analizan descriptivamente, y se utilizan pruebas estadísticas como chi-cuadrado y regresión logística múltiple para explorar asociaciones entre variables y la presencia de errores de medicación.Farmacovigilanciaxiv, 84 páginasapplication/pdfspaUniversidad Nacional de ColombiaBogotá - Ciencias - Maestría en Ciencias - FarmacologíaFacultad de CienciasBogotá, ColombiaUniversidad Nacional de Colombia - Sede Bogotá610 - Medicina y salud::615 - Farmacología y terapéuticaUnidades de cuidados intensivosNegativa del paciente al tratamientoCumplimiento de la medicaciónErrores de medicaciónIntensive care unitsTreatment refusalMedication adherenceMedication errorsUnidad de cuidados intensivosEventos adversosPrevenciónErrores de medicaciónIntensive care unitAdverse eventsPreventionMedication errorsAsesoría farmacológica para prevenir eventos adversos en una unidad de cuidados intensivos en un hospital universitario en Bogotá FASE 1: Frecuencia de eventos adversos y errores de prescripciónPharmacological Counseling to Prevent Adverse Events in an Intensive Care Unit at a University Hospital in Bogotá PHASE 1: Frequency of Adverse Events and Prescription ErrorsTrabajo de grado - Maestríainfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/acceptedVersionTexthttp://purl.org/redcol/resource_type/TMBogotáHeard GC, Sanderson PM, Thomas RD. Barriers to adverse event and error reporting in anesthesia. Anesth Analg. 2012;114(3):604-614.Baillie M. An Account of a Particular Change of Structure in the Human Ovarium. L Med J. 1789;10:322-332Wiedemann HR. [Indication of a current association of hypoplastic and aplastic limb malformations.]. Medizinische Welt. 1961;37:1863-1866.Auzépy P, Durocher A, Gay R, et al. [Severe drug complications: current prevalence amongst patients admitted to adult intensive care units (author’s transl)]. Nouv Press Med. 1979;8(16):1315-1318.Farina ML. Epidemiology of adverse drug reactions in intensive care units. A multicentre prospective survey. Italian Group on Intensive Care Evaluation (IGICE). Eur J Clin Pharmacol. 1987;31(5):507-512Michel P, Quenon JL, De Sarasqueta AM, Scemama O. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ. 2004;328(7433):199-202Laher AE, Enyuma CO, Gerber L, Buchanan S, Adam A, Richards GA. Medication Errors at a Tertiary Hospital Intensive Care Unit. Cureus. 2021;13(12): e20374Albayrak A, Başgut B, Bıkmaz GA, Karahalil B. Clinical pharmacist assessment of drug-related problems among intensive care unit patients in a Turkish university hospital. BMC Health Serv Res. 2022;22(1): 79Sendekie AK, Kasahun AE, Limenh LW, Dagnaw AD, Belachew EA. Clinical and economic impact of adverse drug reactions in hospitalised patients: prospective matched nested case-control study in Ethiopia. BMJ Open. 2023;13(6): e073777da Costa TX, de Almeida Pimenta Cunha MD, do Vale Bezerra PK, Azeredo FJ, Martins RR, Oliveira AG. Incidence of Adverse Drug Reactions in High-Risk Pregnancy: A Prospective Cohort Study in Obstetric Intensive Care. Eur J Clin Pharmacol. 2020;76(2):291-298.Nazer LH, Hawari F, Al-Najjar T. Adverse drug events in critically ill patients with cancer: incidence, characteristics, and outcomes. J Pharm Pract. 2014;27(2):208-213.Benkirane RR, R-Abouqal R, Haimeur CC, et al. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf. 2009;5(1):16-22.Kosenow W, Pfeiffer RA. Micromelia, Haemangioma und Duodenal Stenosis Exhibit, German Pediatric Society, Kassel, 1960. Monatsschr Kinderheilkd. 1961;109:227.UMC. About the WHO Programme for International Drug Monitoring. Accessed December 27, 2023. https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/UMC. The beginner’s guide to pharmacovigilance. Published 2023. Accessed December 27, 2023. https://who-umc.org/about-the-who-programme-for-international-drug-monitoring/the-beginner-s-guide-to-pharmacovigilance/Brown S, Black K, Mrochek S, et al. RADARx: Recognizing, Assessing, and Documenting Adverse Rx events. Proc AMIA Symp. Published online 2000:101-105.Bates DW, Cullen DJ, Laird N, et al. Incidence of Adverse Drug Events and Potential Adverse Drug Events: Implications for Prevention. JAMA. 1995;274(1):29-34.Leape LL, Bates DW, Cullen DJ, et al. Systems Analysis of Adverse Drug Events. JAMA. 1995;274(1):35-43.Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-270.Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109(2):87-94.Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120.Fortescue EB, Kaushal R, Landrigan CP, et al. Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. Pediatrics. 2003;111(4 Pt 1):722-729.Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. Am J Health Syst Pharm. 1998;55(2):165-166SERVICES DOHAH. Guideline for Postmarketing Reporting of Adverse Drug Experiences.; 1992. https://www.fda.gov/media/83280/downloadEdwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet (London, England). 2000;356(9237):1255-1259Cobert B, Biron P. Pharmacovigilance from a to Z : Adverse Drug Event Surveillance. Blackwell Science; 2002Harmonisation International Conference on. E 2 D: Postapproval Safety Data Management.; 2003. https://www.ema.europa.eu/en/documents/scientific-guideline/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-topic-e-2-d-postapproval-safety-data-management-step-5_en.pdfClassen DC, Pestotnik SL, Evans RS, Burke JP. Computerized Surveillance of Adverse Drug Events in Hospital Patients. JAMA. 1991;266(20):2847-2851Schlienger RG, Lüscher TF, Schoenenberger RA, Haefeli WE. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci. 1999;21(3):110-115.Andrews LB, Stocking C, Krizek T, et al. An alternative strategy for studying adverse events in medical care. Lancet (London, England). 1997;349(9048):309-313Institute of Medicine (US) Committee on Quality of Health Care in America. To Err Is Human: Building a Safer Health System. (Kohn LT, Corrigan JM, Molla S. D, eds.). National Academy of Sciences; 2000World Health Organization. The Importance of Pharmacovigilance: An Essential Tool. World Health Organization; 2002.UMC. Glossary of Pharmacovigilance Terms.; 2022. https://learning.who-umc.org/files/114398/SCORM_867007413/scormdriver/indexAPI.htmlBates DW, Boyle DL, Vliet MBV, Schneider J, Leape L. Relationship between medication errors and adverse drug events. J Gen Intern Med. 1995;10(4):199-205.Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001;161(19):2317-2323.Hutchinson TA, Flegel KM, Kramer MS, Leduc DG, Kong HHP. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39(7):533-542. doi:10.1016/0021-9681(86)90198-0Putriana NA, Rusdiana T, Rostinawati T, Akbar MR, Destiani DP. Evaluation of adverse drug reaction in patients warfarin therapy. J Adv Pharm Technol Res. 2022;13(4):291-295.Martys CR. Adverse reactions to drugs in general practice. Br Med J. 1979;2(6199):1194-1197Ejeta F, Aferu T, Feyisa D, et al. Adverse Drug Reaction and Its Predictors Among Psychiatric Patients Taking Psychotropic Medications at the Mizan-Tepi University Teaching Hospital. Neuropsychiatr Dis Treat. 2021;17:3827-3835Abah IO, Dayom WD, Dangiwa DA, et al. Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected Cohort. Afr Health Sci. 2021;21(3):1027-1039Sankhi S, Marasine NR, Sankhi S, Lamichhane R. Adverse Drug Reaction due to Antidepressants among Patients with Depression in a Private Psychiatric Hospital of Nepal. Biomed Res Int. 2020; 16:2020:6682928Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse Drug Events in Hospitalized Patients: Excess Length of Stay, Extra Costs, and Attributable Mortality. JAMA. 1997;277(4):301-306.Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies. JAMA. 1998;279(15):1200-1205.Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4(2): e4439Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Heal care J Int Soc Qual Heal Care. 2003;15 Suppl 1(SUPPL. 1): i49-59.Seddon ME, Jackson A, Cameron C, et al. The Adverse Drug Event Collaborative: a joint venture to measure medication-related patient harm. N Z Med J. 2012;126(1368):9-20Vargas E, Terleira A, Hernando F, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med. 2003;31(3):694-698.Hallas J, Gram L, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol. 1992;33(1):61-68Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care. 2003;12(4):280-285Cooke DI, van der Merwe W, Pudifin DJ. Hospital admissions for adverse reactions to drugs and deliberate self-poisoning. S Afr Med J. 1985;67(19):770-772Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA. 1974;228(6):713-717Rostin M, Pascaud A, Lauque D, Sorbette F, Carles P, Montastruc JL. [An intensive survey of drug surveillance in a medical admissions department]. La Rev Med interne. 1987;8(2):173-179Hallas J, Haghfelt T, Gram LF, Grodum E, Damsbo N. Drug related admissions to a cardiology department; frequency and avoidability. J Intern Med. 1990;228(4):379-384Lakshmanan MC, Hershey CO, Breslau D. Hospital admissions caused by iatrogenic disease. Arch Intern Med. 1986;146(10):1931-1934Einarson TR, Gutierrez LM, Rudis M. Drug-related hospital admissions. Ann Pharmacother. 1993;27(7-8):832-840Karande S, Gogtay NJ, Kshirsagar NA. Improving drug safety monitoring. Indian Pediatr. 2003;40(12):1167-1175.Winterstein AG, Sauer BC, Hepler CD, Poole C, Suárez EC, Kaiser JM. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-1248.McDonnell PJ, Jacobs MR, Monsanto HA, Kaiser JM. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36(9):1331-1336Schneider PJ, Gift MG, Lee YP, Rothermich EA, Sill BE. Cost of medication-related problems at a university hospital. Am J Health Syst Pharm. 1995;52(21):2415-2418.Bates DW, Spell N, Cullen DJ, et al. The Costs of Adverse Drug Events in Hospitalized Patients. JAMA. 1997;277(4):307-311White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999;15(5):445-458.Potts AL, Barr FE, Gregory DF, Wright L, Patel NR. Computerized physician order entry and medication errors in a pediatric critical care unit. Pediatrics. 2004;113(1 Pt 1):59-63Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001;285(16):2114-2120Burnum JF. Letter: Preventability of adverse drug reactions. Ann Intern Med. 1976;85(1):80-81Porter J, Jick H. Drug-related deaths among medical inpatients. JAMA. 1977;237(9):879-881Melmon KL. Preventable drug reactions--causes and cures. N Engl J Med. 1971;284(24):1361-1368Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8(6):289-294Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003;289(9):1107-1116Field TS, Gurwitz JH, Harrold LR, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc. 2004;11(6):492-498Silva CMD da, Besen BAMP, Nassar AP. Characteristics of critically ill patients with cancer associated with intensivist’s perception of inappropriateness of ICU admission: A retrospective cohort study. J Crit Care. 2024;79:154468Sánchez-Sánchez MM, Campos-Asensio C, Arias-Rivera S. Workloads of intensive care nurses. Validity of their estimation using mobile applications and comparison with Nursing Activities Score. Systematised review of the literature. Enferm intensiva. Published online December 12, 2023Leviatan I, Oberman B, Zimlichman E, Stein GY. Associations of physicians’ prescribing experience, work hours, and workload with prescription errors. J Am Med Inform Assoc. 2021;28(6):1074-1080.Oliveira AC de, Garcia PC, Nogueira L de S. Nursing workload and occurrence of adverse events in intensive care: a systematic review. Rev Esc Enferm USP. 2016;50(4):683-694.Dagdelen MS, Gulen D, Ceylan I, Girgin NK. Evaluation of potential drug-drug interactions in intensive care unit. Eur Rev Med Pharmacol Sci. 2021;25(18):5801-5806Arab A, Sheikh-Germchi Z, Habibzadeh S, Sadeghiye-Ahari S, Mostafalou S. Frequency, Predictors, and Outcomes of the Potential Drug-Drug Interactions in the ICUs of Teaching Hospitals in Ardabil, Northwest of Iran During 2019-2020. Hosp Pharm. 2023;58(5):484-490Klopotowska JE, Leopold JH, Bakker T, et al. Adverse drug events caused by three high-risk drug-drug interactions in patients admitted to intensive care units: A multicentre retrospective observational study. Br J Clin Pharmacol. 2024;90(1):164-175Cantor N, Durr KM, McNeill K, et al. Increased Mortality and Costs Associated with Adverse Events in Intensive Care Unit Patients. J Intensive Care Med. 2022;37(8):1075-1081Houso A, Hamdan M, Falana H. Cost benefit analysis of clinical pharmacist interventions in medical intensive care unit in Palestine medical complex: Prospective interventional study. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2022;30(12):1718-1724Alghamdi AA, Keers RN, Sutherland A, Ashcroft DM. Prevalence and Nature of Medication Errors and Preventable Adverse Drug Events in Paediatric and Neonatal Intensive Care Settings: A Systematic Review. Drug Saf. 2019;42(12):1423-1436Resnik DB, Stewart CN. Misconduct versus honest error and scientific disagreement. Account Res. 2012;19(1):56-63Liker JK. The Toyota Way: 14 Management Principles from the World’s Greatest Manufacturer. 2 ED. McGraw-Hill; 2021.Jeremy LE, Soong JL, Lie SA. A cost avoidance study of critical care pharmacists’ interventions in a tertiary institution in Singapore. Am J Health Syst Pharm. 2023;80(5):267-283Althomali A, Altowairqi A, Alghamdi A, et al. Impact of Clinical Pharmacist Intervention on Clinical Outcomes in the Critical Care Unit, Taif City, Saudi Arabia: A Retrospective Study. Pharm (Basel, Switzerland). 2022;10(5):108Muñoz-Pichuante D, Villa-Zapata L. Benefit of Incorporating Clinical Pharmacists in an Adult Intensive Care Unit: A Cost-saving Study. J Clin Pharm Ther. 2020;45(5):1127-1133Leache L, Aquerreta I, Aldaz A, Monedero P, Idoate A, Ortega A. Clinical and economic impact of clinical pharmacist interventions regarding antimicrobials on critically ill patients. Res Social Adm Pharm. 2020;16(9):1285-1289EstudiantesInvestigadoresMaestrosPúblico generalLICENSElicense.txtlicense.txttext/plain; charset=utf-85879https://repositorio.unal.edu.co/bitstream/unal/85485/1/license.txteb34b1cf90b7e1103fc9dfd26be24b4aMD51ORIGINAL79952694.2007.pdf79952694.2007.pdfTesis de Maestría en Ciencias - Farmacologíaapplication/pdf963461https://repositorio.unal.edu.co/bitstream/unal/85485/2/79952694.2007.pdf57aa22fed62f65faad7f720636e99eb1MD52THUMBNAIL79952694.2007.pdf.jpg79952694.2007.pdf.jpgGenerated Thumbnailimage/jpeg6046https://repositorio.unal.edu.co/bitstream/unal/85485/3/79952694.2007.pdf.jpg7c153bd48a516976016a00b09eec12e6MD53unal/85485oai:repositorio.unal.edu.co:unal/854852024-08-22 23:10:06.464Repositorio Institucional Universidad Nacional de Colombiarepositorio_nal@unal.edu.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 |